Preclinical studies have shown that anti-IL-17 antibodies can reduce airway inflammation and remodeling in COPD models, supporting IL-17 as a potential therapeutic target (Yousuf et al., 2019). Here, IL17A is linked to chronic obstructive pulmonary disease.